Pharmacogenomics in treatment of depression and psychosis: an update
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.
Кључне речи:
ADME genes / drug metabolism / personalized medicine / pharmacogenomics / psychiatric geneticsИзвор:
Trends in Pharmacological Sciences, 2022, 43, 12, 1055-1069Издавач:
- Elsevier Ltd
Финансирање / пројекти:
- Grants from the European Research Council (ERC) Advanced Grant (AdG) project HEPASPHER (grant agreement 742020)
- The Swedish Research Council (grants 2021-02732 and 2018-05766)
- PsyCise - Utility of Plasma Drug Level Monitoring and Cyp2c19/Cyp2d6 Genotyping in Dose Personalization of Antidepressants and Antipsychotics (RS-ScienceFundRS-Promis-6066800)
- The Swedish Brain Foundation (grant FO2021-0314),
- The European Union’s Horizon 2020 research and innovation program PSY-PGx under grant agreement 94515
Институција/група
PharmacyTY - JOUR AU - Jukić, Marin AU - Milosavljević, Filip AU - Molden, Espen AU - Ingelman-Sundberg, Magnus PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4307 AB - Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation. PB - Elsevier Ltd T2 - Trends in Pharmacological Sciences T1 - Pharmacogenomics in treatment of depression and psychosis: an update VL - 43 IS - 12 SP - 1055 EP - 1069 DO - 10.1016/j.tips.2022.09.011 ER -
@article{ author = "Jukić, Marin and Milosavljević, Filip and Molden, Espen and Ingelman-Sundberg, Magnus", year = "2022", abstract = "Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.", publisher = "Elsevier Ltd", journal = "Trends in Pharmacological Sciences", title = "Pharmacogenomics in treatment of depression and psychosis: an update", volume = "43", number = "12", pages = "1055-1069", doi = "10.1016/j.tips.2022.09.011" }
Jukić, M., Milosavljević, F., Molden, E.,& Ingelman-Sundberg, M.. (2022). Pharmacogenomics in treatment of depression and psychosis: an update. in Trends in Pharmacological Sciences Elsevier Ltd., 43(12), 1055-1069. https://doi.org/10.1016/j.tips.2022.09.011
Jukić M, Milosavljević F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. in Trends in Pharmacological Sciences. 2022;43(12):1055-1069. doi:10.1016/j.tips.2022.09.011 .
Jukić, Marin, Milosavljević, Filip, Molden, Espen, Ingelman-Sundberg, Magnus, "Pharmacogenomics in treatment of depression and psychosis: an update" in Trends in Pharmacological Sciences, 43, no. 12 (2022):1055-1069, https://doi.org/10.1016/j.tips.2022.09.011 . .